key: cord-0782491-w21kxvt9
authors: Qeadan, Fares; Chehade, Mirna; Tingey, Benjamin; Egbert, Jamie; Dellon, Evan S.; Peterson, Kathryn A.
title: Patients with eosinophilic gastrointestinal disorders have lower in-hospital mortality rates related to COVID-19
date: 2021-09-23
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.09.022
sha: 1871c666081ba1cf1fc5677e64ea8cedf48afb4a
doc_id: 782491
cord_uid: w21kxvt9

nan

Conflict of Interest: MC the larger COVID-19 exposed and positive cohort. 93 Analyses were conducted on the primary cohort of COVID-19 positive patients (Table I) LOS, yet a lower hazard of IVD (aHR: 0.95, 95% CI=0.50-1.79) and in-hospital mortality (aHR: 100 0.38, 95% CI=0.11-1.39). Again, these results were not significant. 101 Analyses were repeated on the larger COVID-19 exposed and positive cohort (Table I) 

The leading causes of death in the US for 2020

Eosinophilia in asthma patients is protective against severe COVID-19 illness

Eosinophilic esophagitis: Is 144 the Th2 inflammation protective against the severe form of COVID-19

Type 2 Immunity 147 and Age Modify Gene Expression of Coronavirus-induced Disease

Journal of Pediatric Gastroenterology and 149 Nutrition

Lack of 151 complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 152 outbreak. The Journal of Allergy and Clinical Immunology: In Practice

Prevalence and 155 characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Type 2 161 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

Eosinopenia could be a 164 relevant prognostic biomarker in patients with coronavirus disease 2019

Hospitalization compared with Chi-square test, maximum LOS compared with Wilcoxon Rank-sum test, time to event survival 191 curves compared with log-rank test

Mean survival times (Wald 95% CI's) restricted to the highest survival time per EGID group (median not used because survival 195 probability did not drop below 50%)

Adjusted for symptoms, procedures, and EGID medications

Adjusted incidence risk ratio

Adjusted exponentiated coefficient

Adjusted hazard ratio

Hospitalization compared with Chi-square test, maximum LOS compared with Wilcoxon Rank-sum test, time to event survival 201 curves compared with log-rank test

Figure 1. Adjusted curves of survival from in-hospital mortality among COVID-19 exposed and positive 206 patients by EGID status